Jeff Yass’s Franklin Genomic Advancements ETF HELX Stock Holding History

Jeff Yass’s Portfolio HELX Stock Details HELX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Buy	+38,272	New	+$1.33M	﹤0.01%	7111
2024 Q2	–	Sell	-6,934	Closed	-$227K	–	12513
2024 Q1	$227K	Sell	6,934 -582	-8%	-$18.2K	﹤0.01%	10333
2023 Q4	$229K	Buy	+7,516	New	+$209K	﹤0.01%	10395

Other funds holding HELX

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jeff Yass's HELX Position: Q2 2026 in Review

Jeff Yass opened a new position in Franklin Genomic Advancements ETF (HELX) in Q2 2026: 38,272 shares worth $1.53M. The stake represents ﹤0.01% of the portfolio and ranks #7111 among its holdings. This is a return to the name: Jeff Yass previously reported a position in HELX as recently as Q1 2024.

Jeff Yass first reported a position in HELX in Q4 2023 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold HELX as of Q2 2026.

Jeff Yass held 38,272 shares of Franklin Genomic Advancements ETF worth $1.53M as of Q2 2026.
Franklin Genomic Advancements ETF was a new Jeff Yass position in Q2 2026.
Franklin Genomic Advancements ETF made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7111 holding.
Jeff Yass first reported a position in Franklin Genomic Advancements ETF in Q4 2023 and has held it in 3 quarters since.
6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.